MCID: OPT010
MIFTS: 38

Optic Papillitis

Categories: Eye diseases, Neuronal diseases, Smell/Taste diseases

Aliases & Classifications for Optic Papillitis

MalaCards integrated aliases for Optic Papillitis:

Name: Optic Papillitis 12 15 17
Papilledema 44 71
Papillitis 12 74

Classifications:



External Ids:

Disease Ontology 12 DOID:10175
MeSH 44 D010211
NCIt 50 C3307
UMLS 71 C0030353 C0155288 C0242420 more

Summaries for Optic Papillitis

MalaCards based summary : Optic Papillitis, also known as papilledema, is related to branch retinal artery occlusion and syphilis, and has symptoms including edema An important gene associated with Optic Papillitis is AQP4 (Aquaporin 4), and among its related pathways/superpathways is Visual Cycle in Retinal Rods. The drugs Minocycline and Doxycycline have been mentioned in the context of this disorder. Affiliated tissues include tongue, eye and endothelial, and related phenotype is immune system.

Wikipedia : 74 Lingual papillae (singular papilla) are the small, nipple-like structures on the upper surface of the... more...

Related Diseases for Optic Papillitis

Diseases related to Optic Papillitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 590)
# Related Disease Score Top Affiliating Genes
1 branch retinal artery occlusion 30.4 CRP AQP4
2 syphilis 30.4 CRP CD4 ACE
3 acute retrobulbar neuritis 30.3 CRP AQP4
4 hypertensive retinopathy 30.3 CRP ACE
5 abducens nerve disease 30.3 CRP AQP4
6 chronic pyelonephritis 30.1 CRP ACE
7 choroiditis 30.0 SAG RBP3 CD4 ACE
8 neuroretinitis 30.0 SAG CRP CD4 ACE
9 retinal vasculitis 29.9 SAG RBP3 CD4 ACE
10 sarcoidosis 1 29.9 CRP CD4 ACE
11 primary syphilis 29.9 CRP CD4
12 secondary syphilis 29.9 CRP CD4
13 facial hemiatrophy 29.9 MRAP CRP
14 multiple cranial nerve palsy 29.9 CRP ACE
15 miliary tuberculosis 29.8 CRP CD4
16 granulomatous angiitis 29.8 CRP ACE
17 otitis externa 29.8 CRP CD4
18 meningitis 29.8 NLRP3 CRP AQP4
19 pleural empyema 29.8 CRP CD4
20 syphilitic meningitis 29.8 CRP CD4
21 chorioretinitis 29.8 SAG RBP3 CRP CD4 ACE
22 actinomycosis 29.7 CRP CD4
23 papilledema 29.7 NLRP3 CRP CD4 AQP4 ACE
24 cryopyrin-associated periodic syndrome 29.7 NLRP3 CRP
25 hypopyon 29.7 RBP3 CRP CD4
26 demyelinating disease 29.7 MOG CD4 AQP4
27 cat-scratch disease 29.6 CRP CD4 ACE
28 exanthem 29.5 NLRP3 CRP CD4 ACE
29 optic nerve disease 29.5 MOG CRP CD4 AQP4 ACE
30 nervous system disease 29.5 MOG CRP CD4 AQP4 ACE
31 cranial nerve palsy 29.4 CRP CD4 AQP4 ACE
32 acute disseminated encephalomyelitis 29.3 MOG AQP4
33 autoimmune disease 29.3 SAG RBP3 MOG CRP
34 iritis 29.3 RBP3 MRAP CRP CD4 ACE
35 neurosarcoidosis 29.2 MOG CRP CD4 AQP4 ACE
36 peripheral nervous system disease 29.1 MOG CRP CD4 AQP4 ACE
37 crohn's disease 29.1 NLRP3 CRP CD4
38 iridocyclitis 28.7 TNFRSF10A RBP3 MRAP CRP CD4 ACE
39 panuveitis 28.4 TNFRSF10A SAG RBP3 MRAP CRP CD4
40 papilloma of choroid plexus 11.1
41 optic neuritis 11.1
42 kidney papillary necrosis 11.1
43 hydrocephalus 11.0
44 colloid cysts of third ventricle 10.9
45 retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache syndrome 10.9
46 rosette-forming glioneuronal tumor 10.9
47 intracranial hypertension, idiopathic 10.6
48 pseudopapilledema 10.5
49 vascular myelopathy 10.4 MOG AQP4
50 balo concentric sclerosis 10.4 MOG AQP4

Graphical network of the top 20 diseases related to Optic Papillitis:



Diseases related to Optic Papillitis

Symptoms & Phenotypes for Optic Papillitis

UMLS symptoms related to Optic Papillitis:


edema

MGI Mouse Phenotypes related to Optic Papillitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.28 ACE AQP4 CD4 CRP MOG NLRP3

Drugs & Therapeutics for Optic Papillitis

Drugs for Optic Papillitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
2
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
3
Lymecycline Approved, Investigational Phase 4 992-21-2 5280963
4
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
5
Ranibizumab Approved Phase 4 347396-82-1 459903
6
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
7
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
8 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
9
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
10
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
11
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
12
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
13
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
14
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
15 Angiogenesis Inhibitors Phase 4
16 Mitogens Phase 4
17 Endothelial Growth Factors Phase 4
18 Pharmaceutical Solutions Phase 4
19 Anti-Inflammatory Agents Phase 4
20 Gastrointestinal Agents Phase 4
21 Hormones Phase 4
22 Hormone Antagonists Phase 4
23 BB 1101 Phase 4
24 HIV Protease Inhibitors Phase 4
25 Antineoplastic Agents, Hormonal Phase 4
26 glucocorticoids Phase 4
27
protease inhibitors Phase 4
28 Antiemetics Phase 4
29 Methylprednisolone Acetate Phase 4
30
Guaifenesin Approved, Investigational, Vet_approved Phase 2, Phase 3 93-14-1 3516
31
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
32
Codeine Approved, Illicit Phase 2, Phase 3 76-57-3 5284371
33
Aspirin Approved, Vet_approved Phase 2, Phase 3 50-78-2 2244
34
Acetazolamide Approved, Vet_approved Phase 2, Phase 3 59-66-5 1986
35
Naproxen Approved, Vet_approved Phase 2, Phase 3 22204-53-1 1302 156391
36
Ibuprofen Approved Phase 2, Phase 3 15687-27-1 3672
37 Anticonvulsants Phase 2, Phase 3
38 Respiratory System Agents Phase 2, Phase 3
39 Analgesics, Non-Narcotic Phase 2, Phase 3
40 Fibrinolytic Agents Phase 2, Phase 3
41 Narcotics Phase 2, Phase 3
42 Cyclooxygenase Inhibitors Phase 2, Phase 3
43 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
44 Antitussive Agents Phase 2, Phase 3
45 Analgesics Phase 2, Phase 3
46 Analgesics, Opioid Phase 2, Phase 3
47 diuretics Phase 2, Phase 3
48 Chlorpheniramine, phenylpropanolamine drug combination Phase 2, Phase 3
49 Antipyretics Phase 2, Phase 3
50 Platelet Aggregation Inhibitors Phase 2, Phase 3

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 Prospective Open-label Phase IV Trial to Investigate the Frequency of Optic Disc Swelling, Idiopathic Intracranial Hypertension and Dry Eye Symptoms Under Antiacne Medication Treatment Unknown status NCT02149615 Phase 4
2 Treatment of Diabetic Macular Edema (DME) With Intravitreal Anti-vascular Endothelial Growth Factor (Anti-VEGF) and Prompt Versus Deferred Focal Laser During Long-term Follow-up and Identification of Prognostic Retinal Markers Completed NCT03590444 Phase 4 Ranibizumab 0.5 MG/0.05 ML Intraocular Solution
3 Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study Completed NCT01486238 Phase 4 Macugen® pegaptanib sodium
4 Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) When Placed Within the Lower Eye Lid Canaliculus or Both the Upper and Lower Canaliculi for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker. Not yet recruiting NCT04501367 Phase 4 Dexamethasone Intracanalicular Insert, 0.4 mg;Dexamethasone Intracanalicular Insert, 0.4 mg;Prednisone acetate 1%
5 A Multicenter, Double-blind, Randomized, Placebo-controlled Study of Weight-Reduction and/or Low Sodium Diet Plus Acetazolamide vs Diet Plus Placebo in Subjects With Idiopathic Intracranial Hypertension With Mild Visual Loss Completed NCT01003639 Phase 2, Phase 3 Acetazolamide;Placebo
6 Ozurdex in Treatment of Macular Edema Post Membrane Peeling Completed NCT01273727 Phase 2, Phase 3 Dexamethasone;dexamethasone
7 Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF Therapy Comparing Syringe Preparation Time Using Ranibizumab Vial and Pre-filled Syringe Completed NCT03071055 Phase 2 Ranibizumab Injection [Lucentis]
8 A Long-Term Outcome Study With the IL-1 Receptor Antagonist Anakinra/Kineret in Patients With Neonatal Onset Multisystem Inflammatory Disease (NOMID/CINCA Syndrome) A Therapeutic Approach to Study the Pathogenesis of This Disease Terminated NCT00069329 Phase 1, Phase 2 anakinra
9 Evaluation of the Feasibility, Safety and Efficacy of Venous Stenting for Internal Jugular Vein Stenosis Unknown status NCT03373292 Phase 1
10 Non-invasive Absolute Intracranial Pressure (ICP) Measurement in Patients With Open-angle Glaucoma and Papilledema Unknown status NCT02410148
11 Cerebral Venous Sinus Thrombosis: Re-exploration of Clinical Assessment Unknown status NCT03273179
12 Ocular Point of Care Ultrasound (POCUS) to Detect Optic Disc Swelling in Comparison to Ophthalmologic Examination Unknown status NCT02992262
13 OCT Imaging of Papilledema in Pediatric Idiopathic Intracranial Hypertension Unknown status NCT02665858
14 Effectiveness of Multimodal Imaging for the Evaluation of Retinal Oedema And New vesseLs in Diabetic Retinopathy Unknown status NCT03490318
15 LUMINOUS: Study to Observe the Effectiveness and Safety of Ranibizumab Through Individualized Patient Treatment and Associated Outcomes Completed NCT01318941 Ranibizumab
16 Retinal Nerve Fibre Layer in Uveitic Secondary Glaucoma Completed NCT01170481
17 Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD for Treatment of Ocular Inflammation Associated With Cataract Surgery Completed NCT01847638 Prolensa (bromfenac 0.07%);Ilevro (nepafenac 0.3%)
18 Determination of Normal Measures of Optic Nerve Sheath Diameter in Children Recruiting NCT03178760
19 Precise High Resolution MRI to Increase Accuracy and Gain Confidence to Diagnose Patients With Optic Disc Edema Recruiting NCT04448613
20 Evaluating Raised Intracranial Pressure Using MR Elastography Active, not recruiting NCT03096743
21 Prevalence of Ocular Manifestations in Inflammatory Rheumatic Diseases Active, not recruiting NCT03753893
22 A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema Available NCT01487044 Macugen (Pegaptanib Sodium)
23 Resistant Diabetic Macular Edema and Suprachoroidal Injection Not yet recruiting NCT04690608 Early Phase 1 Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1
24 Ovarian Cancer Early Detection Screening Program Terminated NCT01292733 Early Phase 1
25 Incidence and Causes of Disc Edema in Patients With Chronic Kidney Disease Withdrawn NCT00769834

Search NIH Clinical Center for Optic Papillitis

Cochrane evidence based reviews: papilledema

Genetic Tests for Optic Papillitis

Anatomical Context for Optic Papillitis

MalaCards organs/tissues related to Optic Papillitis:

40
Tongue, Eye, Endothelial, Kidney, Cortex, Retina, Spinal Cord

Publications for Optic Papillitis

Articles related to Optic Papillitis:

(show top 50) (show all 773)
# Title Authors PMID Year
1
Papillitis, a Rare Cytomegalovirus Manifestation in an Immunocompetent Host. 61
32235231 2021
2
12. Review of diabetic papillitis. 61
33549309 2021
3
Mucocutaneous disease and related clinical characteristics in hospitalized children and adolescents with COVID-19 and multisystem inflammatory syndrome in children. 61
33323343 2021
4
Vitreopapillary Traction Masquerading as Papillitis and Papilledema. 61
33417415 2021
5
Anti-GFAP neuroinflammation with synchronous bilateral papillitis and characteristic imaging. 61
33334873 2020
6
Papillitis with retinal venous congestion and intraocular inflammation. 61
32984653 2020
7
Bilateral diabetic papillopathy developed after starting insulin treatment. Potential toxic effect of insulin? A case report. 61
33353425 2020
8
Etiology of Optic Disc Swelling in a Tertiary Care Center in Nigeria. 61
33355822 2020
9
Anti-VEGF Therapy and Retinal Photocoagulation to Prevent Recurrence of Central Retinal Vein Occlusion: Two Case Reports of Young Patients. 61
33300598 2020
10
Factors associated with ocular adverse event after immune checkpoint inhibitor treatment. 61
32556494 2020
11
Reactive AA Amyloidosis in the setting of infective endocarditis manifesting as bilateral orbitopathy and choroidopathy. 61
33394958 2020
12
HYPERAUTOFLUORESCENT SPOTS IN ACUTE OCULAR TOXOPLASMOSIS: A New Indicator of Outer Retinal Inflammation. 61
31923122 2020
13
Tailored access to the hepatobiliary system in post-bariatric patients: a tertiary care bariatric center experience. 61
31993808 2020
14
Rapidly progressive vision loss due to fulminant idiopathic intracranial hypertension: a diagnostic and management dilemma. 61
33148594 2020
15
Optical coherence tomography angiography in neuro-ophthalmology: Current clinical role and future perspectives. 61
33157113 2020
16
Ocular syphilis 61
33161392 2020
17
Inflammatory choroiditis and papillitis from Crohn's disease in a child. 61
33127473 2020
18
Lyme disease atypically presenting with a singular symptom: Unilateral chorioretinitis. 61
32998513 2020
19
Tocilizumab Employment in the Treatment of Resistant Juvenile Idiopathic Arthritis Associated Uveitis. 61
33021415 2020
20
Homonymous visual field defects in patients with multiple sclerosis: results of computerised perimetry and optical coherence tomography. 61
33035355 2020
21
Vitreomacular traction associated with papillitis. 61
32490288 2020
22
Atypical papillitis: An isolated manifestation of Lyme disease. 61
31167569 2020
23
Reversible retinoschisis following high voltage electrical injury evaluated with optical coherence tomography and electrophysiology. 61
32642595 2020
24
Implications of pars planitis-associated cystoid macular edema on visual outcome and management in children. 61
32346784 2020
25
Recurrent ascending cholangitis with acute pancreatitis and pancreatic atrophy caused by a juxtapapillary duodenal diverticulum: A case report and literature review. 61
32629744 2020
26
Investigation of oral atopic diseases: Correlation between geographic tongue and fungiform papillary glossitis. 61
32540362 2020
27
Long-term prophylaxis in an immunocompetent patient with Cytomegalovirus retinitis: a case report and review of literature. 61
32588149 2020
28
BILATERAL SEROUS RETINAL DETACHMENT AND UVEITIS ASSOCIATED WITH PEMBROLIZUMAB TREATMENT IN METASTATIC MELANOMA. 61
32243282 2020
29
Development of Acute Vogt-Koyanagi-Harada-like Syndrome during the Treatment Course with Vemurafenib for Metastatic Melanoma. 61
31161956 2020
30
Resurgence of ocular syphilis in British Columbia between 2013-2016: a retrospective chart review. 61
31889521 2020
31
[Clinical characteristics, treatment and prognosis of myelin oligodendrocyte glycoprotein antibody-associated optic neuritis in children]. 61
32187912 2020
32
Incipient Syphilitic Papillitis. 61
32076443 2020
33
Diagnosis of Syphilitic Bilateral Papillitis Mimicking Papilloedema. 61
31855531 2020
34
A Case of Cerebral Granuloma and Optic Papillitis due to Brucella sp. 61
32733718 2020
35
Clinical Features of Ocular Syphilis: a Retrospective Clinical Study in an Italian Referral Centre. 61
32036734 2020
36
Lightning Injury to Eye: Brief Review of the Literature and Case Series. 61
32184548 2020
37
Acute Visual Loss Secondary to Arnold Chiari Type I Malformation Completely Resolving After Decompressive Posterior Fossa Surgery. 61
33239924 2020
38
Demographic and Clinical Features of Pediatric Uveitis in Israel. 61
30332547 2020
39
Case report: Bilateral uveitis and papillitis secondary to treatment with pembrolizumab. 61
31755465 2019
40
Combination of CT findings can reliably predict radiolucent common bile duct stones: a novel approach using a CT-based nomogram. 61
31115625 2019
41
Choroidal Structural Changes in Patients with Birdshot Chorioretinopathy. 61
31714872 2019
42
Papillitis in Neurosyphilis. 61
31915744 2019
43
Delayed tacrolimus-induced optic neuropathy. 61
31872814 2019
44
Leber's idiopathic stellate neuroretinitis: diagnostic and therapeutic conflicts. 61
31053369 2019
45
Optic nerve involvement in ocular toxoplasmosis: 12 year data from a tertiary referral center in Turkey. 61
30970124 2019
46
MULTIMODAL IMAGING OF IGG4-RELATED PAPILLITIS AND RETINAL DISEASE. 61
31343561 2019
47
An unusual case of tuberculous optic neuropathy associated with choroiditis. 61
31238469 2019
48
Ocular manifestations in tuberculosis cases with HIV in Nepal. 61
32792688 2019
49
Papillitis and neuroretinitis of tuberculous etiology. 61
30718012 2019
50
Coexistence of Papillitis and Posterior Placoid Chorioretinopathy as the Presenting Symptoms of Syphilis-Human Immunodeficiency Virus Coinfection. 61
31312245 2019

Variations for Optic Papillitis

Expression for Optic Papillitis

Search GEO for disease gene expression data for Optic Papillitis.

Pathways for Optic Papillitis

Pathways related to Optic Papillitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.77 SAG RBP3 CRP

GO Terms for Optic Papillitis

Cellular components related to Optic Papillitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 MOG CD4 AQP4 ACE

Molecular functions related to Optic Papillitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.1 TNFRSF10A NLRP3 MRAP CRP CD4 AQP4

Sources for Optic Papillitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....